MedicaidAdministrativeMedium impact
Newsletter Vol 33, No.16
New Jersey Medicaid·NJ · Pharmacy, Family Medicine, Internal Medicine +2 more·Pharmacy
Effective date
Sep 1, 2023
We identified it
Jun 20, 2026
Summary
New Jersey Medicaid/NJ FamilyCare providers must comply with SUPPORT Act requirements by checking the New Jersey Prescription Monitoring Program (NJPMP) before prescribing or dispensing Controlled Dangerous Substances (CDS), gabapentin, and Human Growth Hormone (HGH). The state will conduct routine compliance reviews to validate proper NJPMP usage. This is a reminder/enforcement notification of existing obligations rather than a new requirement.
Action Required
Immediately: Providers and pharmaceutical service providers must ensure they are accessing and utilizing the NJPMP database (https://newjersey.pmpaware.net) prior to prescribing or dispensing any Controlled Dangerous Substances, gabapentin, or Human Growth Hormone for Medicaid/NJ FamilyCare beneficiaries. Billing and clinical teams should: (1) Verify all prescribers have active NJPMP access and know how to query the system; (2) Implement workflow checks to document NJPMP review before CDS/gabapentin/HGH prescriptions are issued; (3) Train staff on compliance requirements outlined at https://www.njconsumeraffairs.gov/pmp/Pages/regulations.aspx; (4) Retain this newsletter for audit documentation. The Division of Medical Assistance and Health Services will conduct compliance reviews. Non-compliance may result in regulatory action or claim denials. Contact Gainwell Technologies Provider Services at 1-800-776-6334 with questions.